Citations

Clear

116 citation(s) found for "Davis, Mark".

Direct oral anticoagulant medications in calciphylaxis
King, Brian J., McEvoy, Marian T., Shields, Raymond C., McBane, Robert D. , McCarthy, James T. , Davis, Mark D.P. , El-Azhary, Rokea A, McBane, Robert , el‐Azhary, Rokea A.

Mayo Clinic

International Journal of Dermatology | August 31, 2017 | Volume: 56 | Issue: 10 | Pages: 1065-1070

10.1111/ijd.13685 | PMID 28856671 Get It

AbstractBackgroundRecent studies suggest that calciphylaxis is a thrombotic condition in which arteriolar thrombosis leads to painful skin infarcts and consequent morbidity and mortality. Paradoxically, warfarin is implicated as a risk factor for calciphylaxis. Our objective is to report the use of oral direct thrombin and factor Xa inhibitors (termed direct oral anticoagulants [DOACs]) in patients with calciphylaxis.MethodsWe retrospectively reviewed records of 16 patients with calciphylaxis who received concomitant administration of novel anticoagulants. Patient data, including demographics, comorbidities, other treatments, and adverse events, were abstracted from the health records.ResultsEleven patients (69%) had chronic kidney disease (stage ≥3A), and eight (50%) received dialysis. Apixaban was the most frequently used agent (n = 11 [69%]). Dabigatran (n = 4 [25%]) and rivaroxaban (n = 2 [13%]) were reserved for patients with mild renal impairment (stage ≤2). One clinically relevant but nonmajor bleeding event occurred. There were no major bleeding events. Nine patients (56%) were alive at last follow‐up, and five (31%) had complete resolution of their calciphylaxis (mean follow‐up, 523 days; range, 26–1884 days).ConclusionDOACs were safe and well tolerated in patients with calciphylaxis, in this initial experience. Several patients had improvement or resolution of calciphylaxis in response to therapy that included DOACs. The degree of renal impairment should guide DOAC choice. Randomized trials are required to determine treatment efficacy.
Delayed Patch-Test Reading After 5 Days: An Update From the Mayo Clinic Contact Dermatitis Group
Chaudhry, Hafsa, Drage, Lisa A., Hall, Matthew R., Killian, Jill M. , Prakash, Amy V., Yiannias, James A. , Davis, Mark D.P. , Cantwell, Hafsa M. , Chaudhry, Hafsa M, el‐Azhary, Rokea A.

Mayo Clinic

Dermatitis® | July 18, 2017 | Volume: 28 | Issue: 4 | Pages: 253-260

10.1097/der.0000000000000297 | PMID 28719473 Get It

Background Patch-test readings after day 5 have previously been used to identify delayed reactions to metals and topical antibiotics. Objective The aims of this study were to identify allergens for which late readings (beyond day 5) would be most valuable and to compare our results with our previous study on delayed patch-test readings. Methods This was a retrospective study of 298 patients who underwent metal and corticosteroid series patch testing from January 1, 2007, through December 31, 2013. Patch-test readings were conducted on days 3 and 5 and at least once sometime between days 7 and 14. All reactions were examined at each reading. Conclusions These results were concordant with our previous findings that additional readings after day 7 are particularly useful for identifying reactions to metals (gold, cobalt, beryllium, palladium), specific preservatives (dodecyl gallate, propolis), and the topical antibiotic neomycin. New delayed reactions to bacitracin, p -phenylenediamine, and topical corticosteroids were not seen in this cohort.
An unusual case of methicillin‐resistant Staphylococcus aureus necrotic soft tissue infection of the lip
Kamboj, Amrit K. , Cotter, Thomas G. , McEvoy, Marian T., Davis, Mark Denis D., Miller, Donna , Davis, Mark D., Miller, Donna M, Miller, Donna M , Cotter, T G

Mayo Clinic

International Journal of Dermatology | May 17, 2017 | Volume: 56 | Issue: 12 | Pages: 1475-1477

10.1111/ijd.13630 | PMID 28512754 Get It

Early clinical presentations and progression of calciphylaxis
Ghosh, Toshi, Winchester, Daniel S., Davis, Mark D. P. , Comfere, Nneka I. , Davis, Mark D.P. , el‐Azhary, Rokea A.

Mayo Clinic

International Journal of Dermatology | April 24, 2017 | Volume: 56 | Issue: 8 | Pages: 856-861

10.1111/ijd.13622 | PMID 28436018 Get It

AbstractBackgroundUntreated calciphylaxis is a fatal disease of intra‐ and extravascular calcification, most commonly presenting in end‐stage renal disease (ESRD) patients. While early identification is critical for timely treatment, early‐stage clinical and histopathological descriptions have not, to our knowledge, been elucidated. As early clinical recognition is essential to prompt definitive histopathological diagnosis, this study describes a range of clinical and histopathological manifestations of early‐stage calciphylaxis.MethodsFive patients with clinical photographs of lesions of early‐phase calciphylaxis were chosen from a recent database of 101 patients. Their clinical histories were reviewed and correlated with their respective clinical and histopathological images of early‐stage disease and progression of the disease.ResultsTwo of the five patients were identified early to have calciphylaxis and were promptly initiated on aggressive, multimodal therapy, resulting in complete resolution and remission of calciphylaxis. The other three patients were also recognized in early stages, one without renal disease, although the disease had progressed to more advanced stages associated with greater morbidity and mortality.ConclusionsThese cases demonstrate that calciphylaxis may be clinically misdiagnosed due to ill‐defined presentations, particularly in the early stages without the characteristic features of livedo racemosa and ulceration. However, recognition in the early stages is critical to implement timely treatment. As such, definitively diagnostic skin biopsy should be considered early in suspected cases to confirm the diagnosis of calciphylaxis and ensure prompt management of this lethal disease.
A wake‐up call to dermatologists – climate change affects the skin
Andersen, Louise K. , Davis, Mark D. P. , Davis, Mark D.P.

Mayo Clinic

International Journal of Dermatology | April 24, 2017 | Volume: 56 | Issue: 10 | Pages: No page available

10.1111/ijd.13617 | PMID 28436009 Get It

Burning mouth syndrome: results of screening tests for vitamin and mineral deficiencies, thyroid hormone, and glucose levels—experience at Mayo Clinic over a decade
Verenzuela, Claudia S. Morr, Davis, Mark D.P. , Bruce, Alison J., Torgerson, Rochelle R. , Morr Verenzuela, Claudia S

Mayo Clinic

International Journal of Dermatology | April 24, 2017 | Volume: 56 | Issue: 9 | Pages: 952-956

10.1111/ijd.13634 | PMID 28436021 Get It

AbstractBackgroundBurning mouth syndrome (BMS) is a disorder characterized by chronic mouth pain in the absence of objective clinical abnormalities. Vitamin or mineral deficiencies may have a role in BMS, but data regarding the prevalence and relevance of hematinic deficiencies are conflicting. We aimed to determine the frequency of specific laboratory abnormalities in patients with BMS.MethodsWe retrospectively reviewed the results of screening blood tests in patients with BMS at our institution between January 2003 and December 2013.ResultsAmong 659 patients with BMS, the most common decreased values or deficiencies were vitamin D3 (15%), vitamin B2 (15%), vitamin B6 (5.7%), zinc (5.7%), vitamin B1 (5.3%), thyrotropin (TSH) (3.2%), vitamin B12 (0.8%), and folic acid (0.7%). Laboratory values for fasting blood glucose and TSH were increased in 23.7% and 5.2%, respectively.ConclusionsIn patients with symptoms of BMS, our results suggest it is reasonable to screen for fasting blood glucose, vitamin D (D2 and D3), vitamin B6, zinc, vitamin B1, and TSH. Deficiencies of vitamin B12 and folic acid were rare (<1% abnormal).
Zika virus: skin is commonly involved
Andersen, Louise K. , Davis, Mark D. P. , Azulay‐Abulafia, Luna , Davis, Mark D.P.

Mayo Clinic

International Journal of Dermatology | January 19, 2017 | Volume: 56 | Issue: 4 | Pages: No page available

10.1111/ijd.13509 | PMID 28102537 Get It

Acute generalized exanthematous pustulosis: clinical characteristics, etiologic associations, treatments, and outcomes in a series of 28 patients at Mayo Clinic, 1996–2013
Alniemi, Dema T., Wetter, David A. , Bridges, Alina G. , Davis, Mark D. P. , Camilleri, Michael , McEvoy, Marian T., El-Azhary, Rokea A, el‐Azhary, Rokea A. , Davis, Mark D.P.

Mayo Clinic

International Journal of Dermatology | January 13, 2017 | Volume: 56 | Issue: 4 | Pages: 405-414

10.1111/ijd.13434 | PMID 28084022 Get It

AbstractBackgroundAcute generalized exanthematous pustulosis (AGEP) is a rare skin condition typically caused by medications. The objective of this study was to examine the clinical features, causes, and outcomes of AGEP at a sole tertiary care center.MethodsA retrospective review of patients with AGEP (European Study of Severe Cutaneous Adverse Reactions score of ≥ 5) seen at Mayo Clinic (Rochester, MN, USA) between January 1, 1996, and December 31, 2013, was conducted.ResultsOf 28 patients (mean age at onset: 56 years), 17 (61%) were women. The development of AGEP was attributed to medications in 25 patients (89%), with clindamycin the most common culprit (six patients). Three patients (11%) had mucous membrane involvement, and 21 (75%) showed systemic involvement. Ten patients (36%) received systemic corticosteroids for treatment of AGEP. Skin findings resolved within 15 days in 26 patients (93%) (mean time to resolution: 7.6 days). In three patients (11%), generalized skin eruptions or dermatitis developed weeks to months after the resolution of AGEP. Twenty‐four patients (86%) had a personal history of drug reactions before the development of AGEP.ConclusionsA previous history of drug reactions and clindamycin causation were more common in the present cohort than in prior reports. A small subset of patients experienced new‐onset non‐AGEP skin eruptions within a few months of the resolution of AGEP.
Epidermal Nerve Fiber Quantification in Patients With Erythromelalgia
Mantyh, William G. , Dyck, P. James B. , Engelstad, JaNean , Litchy, William J. , Sandroni, Paola , Davis, Mark D.P.

Mayo Clinic

JAMA Dermatology | December 7, 2016 | Volume: 153 | Issue: 2 | Pages: 162

10.1001/jamadermatol.2016.4404 | PMID 27926760 Get It

Climate change and the epidemiology of selected tick‐borne and mosquito‐borne diseases: update from the International Society of Dermatology Climate Change Task Force
Andersen, Louise K. , Davis, Mark D.P.

Mayo Clinic

International Journal of Dermatology | October 7, 2016 | Volume: 56 | Issue: 3 | Pages: 252-259

10.1111/ijd.13438 | PMID 27696381 Get It

AbstractClimate change refers to variation in the climate of a specific region or globally over time. A change has been reported in the epidemiology of tick‐ and mosquito‐borne diseases in recent decades. Investigators have postulated that this effect may be associated with climate change. We reviewed the English‐language literature describing changes in the epidemiology of specific tick‐ and mosquito‐borne diseases, including the tick‐borne diseases of Lyme disease, tularemia, Crimean‐Congo hemorrhagic fever, Mediterranean spotted fever, and Rocky Mountain spotted fever and the mosquito‐borne diseases of dengue, malaria, West Nile virus infection, Ross River virus disease, and Barmah Forest virus disease. We postulate that the changing epidemiology of tick‐ and mosquito‐borne diseases is related to climate change.